

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PHIGENIX, INC.

Petitioner

v.

IMMUNOGEN, INC.

Patent Owner

CASE IPR2014-00676
U.S. Patent No. 8,337,856

IMMUNOGEN, INC.'S EXHIBIT LIST

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

<i>ImmunoGen Exhibit #</i>	<i>Description</i>
2001	Hamel, E., "Natural Products Which Interact with Tubulin in the Vinca Domain: Maytansine, Rhizoxin, Phomopsin A, Dolastatins 10 and 15 and Halichondrin B," <i>Pharmacy Therapy</i> 55:31-51 (1992)
2002	Maytansine, Annual Report to the Food and Drug Administration; <i>Investigational Drug Branch Cancer Therapy Evaluation Program Division of Cancer Treatment National Cancer Institute</i> , 1-21 (1984)
2003	Cabanillas, F., <i>et al.</i> , "Results of a Phase II Study of Maytansine in Patients with Breast Carcinoma and Melanoma," <i>Cancer Treatment Reports</i> 63: 507-509 (1979)
2004	Rosenthal, S., <i>et al.</i> , "Phase II Study of Maytansine in Patients with Advanced Lymphomas: An Eastern Cooperative Oncology Group Pilot Study," <i>Cancer Treatment Reports</i> 64: 1115-1117 (1980)
2005	Ravry, M., <i>et al.</i> , "Phase II Evaluation of Maytansine (NSC 153858) in Advanced Cancer," <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> 8: 148-150 (1985)
2006	Blättler, W., <i>et al.</i> , "Immunoconjugates," in <i>Cancer Therapeutics: Experimental and Clinical Agents</i> , Chapter 17, pp. 371-394 (1996)
2007	Dubowchik, G. and Walker, M.A., "Receptor-Mediated and Enzyme-Dependent Targeting of Cytotoxic Anticancer Drugs," <i>Pharmacology & Therapeutics</i> 83: 67-123 (1999)
2008	Cheson, B., <i>et al.</i> , "2011 Top Game Changers in Oncology," pp. 1-9 (2011) available at www.medscape.com at http://www.medscape.com/viewarticle/754136_print (last accessed July 30, 2014)

<p>2009</p>	<p>Wildiers, H., <i>et al.</i>, "Late Breaking Abstract: T-DM1 for HER2-positive metastatic breast cancer (MBC): Primary result from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice," <i>European Cancer Congress 2013</i>, pp. 1-2, available at http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx?abstractid=8879 (<i>last accessed July 28, 2014</i>)</p>
<p>2010</p>	<p>Tolcher, A., <i>et al.</i>, "Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer," <i>Journal of Clinical Oncology</i> 17: 478-484 (1999)</p>
<p>2011</p>	<p>Elias, D., <i>et al.</i>, "Monoclonal Antibody KS1/4-Methotrexate Immunoconjugate Studies in Non-Small Cell Lung Carcinoma," <i>American Journal of Respiratory and Critical Care Medicine</i> 150: 1114-1122 (1994)</p>
<p>2012</p>	<p>Krop, I., <i>et al.</i>, "Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial," <i>Lancet Oncology</i> 15: 689-699 (2014)</p>
<p>2013</p>	<p>Figuroa-Magalhães, M. and Stearns, V., "T-DM1 adds to the Armamentarium for Targeting Advanced HER2-Positive Breast Cancer," <i>Community Oncology</i> 10: 69-73 (2013)</p>
<p>2014</p>	<p>Interview Summary dated September 14, 2009 from the File History of U.S. Patent No. 8,337,856, p. 1.</p>
<p>2015</p>	<p>Cao, Y., <i>et al.</i>, "Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu," <i>Molecular Cancer Therapeutics</i> 12: 979-991 (2013)</p>
<p>2016</p>	<p>Cao, Y., and Rosenblum, M.G., "Design, Development, and Characterization of Recombinant Immunotoxins Targeting HER2/neu," in <i>Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications</i>, Chapter 18, pp. 319-348 (2013)</p>

<p>2017</p>	<p>Engert, A. <i>et al.</i>, "The Emerging Role of Ricin in A-Chain Immunotoxins in Leukemia and Lymphoma" in <i>Clinical Applications of Immunotoxins</i> by Frankel, A.E., (Ed.), pp. 1-23 (1998)</p>
<p>2018</p>	<p>Roth, B., <i>et al.</i>, "Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology," <i>Journal of Clinical Oncology</i> 31: 131-161, 2063 (2013)</p>
<p>2019</p>	<p>Gochenauer, G., "Roche/Genentech's "Magic Bullet" in HER2+ Breast Cancer," available at http://www.kantarhealth.com/blog/oncology/gordon-gochenauer/2012/06/03/Roche_Genentech_Magic_Bullet_in_HER2_Breast_Cancer (<i>last accessed July 30, 2014</i>) pp. 1-2 (2012)</p>
<p>2020</p>	<p>Miller, K., <i>et al.</i>, "T-DM1: Golden Age in HER2+ Breast Cancer?" pp. 1-6 (2012) available at www.medscape.com at http://www.medscape.com/viewarticle/765248 (<i>last accessed July 30, 2014</i>)</p>
<p>2021</p>	<p>"FDA Approves New Late-Stage Breast Cancer Drug Kadcyla," pp. 1-4 (2013) available at http://www.cbsnews.com/news/fda-approves-new-late-stage-breast-cancer-drug-kadcyla/ (<i>last accessed July 28, 2014</i>)</p>
<p>2022</p>	<p>"Breast Cancer Drug Targets Tumor Cells, Spares Healthy Ones," pp. 1-2 (2013) available at http://abc7.com/archive/9003043/ (<i>last accessed July 28, 2014</i>)</p>
<p>2023</p>	<p>Helwick, C., "Refining Current Treatments and Looking Ahead in HER2-positive Breast Cancer," <i>Best of ASCO Supplement</i> 3:1-2 (2012)</p>
<p>2024</p>	<p>Herper, M., "A Triumph In Breast Cancer--And Another Expensive Drug," pp. 1-3 (2013) available at http://www.forbes.com at http://www.forbes.com/sites/matthewherper/2013/02/22/a-triumph-in-breast-cancer-and-another-expensive-drug/ (<i>last accessed July 28, 2014</i>)</p>

2025	Kadcyla™ Prescribing Information, pp. 1-21(2013)
2026	Hurvitz, S., <i>et al.</i> , "Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer," <i>Journal of Clinical Oncology</i> 31: 1157-1163, 2977 (2013)
2027	Nandini, D., <i>et al.</i> , "T-DM1: A Giant Step Forwards in HER2 Therapeutics," <i>Cancer Therapy</i> 9: 45-54 (2013)
2028	September 17, 2010 Office Communication from the File History of U.S. Patent No. 8,337,856, pp. 1-2.
2029	Pai-Scherf, L., <i>et al.</i> , "Hepatotoxicity in Cancer Patients Receiving erb-38, a Recombinant Immunotoxin That Targets the erbB2 Receptor," <i>Clinical Cancer Research</i> 5: 2311-2315 (1999)
2030	Pai, L., <i>et al.</i> , "Clinical Evaluation of Intraperitoneal <i>Pseudomonas</i> Exotoxin Immunoconjugate OVB3-PE in Patients With Ovarian Cancer," <i>Journal of Clinical Oncology</i> 9: 2095-2103 (1991)
2031	Gould, B., <i>et al.</i> , "Phase I Study of an Anti-Breast Cancer Immunotoxin by Continuous Infusion: Report of a Targeted Toxic Effect Not Predicted by Animal Studies," <i>Journal of the National Cancer Institute</i> 81: 775-781 (1989)
2032	Drebin, J., <i>et al.</i> , "Monoclonal Antibodies Specific for the <i>neu</i> Oncogene Product Directly Mediate Anti-Tumor Effects <i>in vivo</i> ," <i>Oncogene</i> 2:387-394 (1988)
2033	Stancovski, I., <i>et al.</i> , "Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth," <i>Proc. Natl. Acad. Sci.</i> 88: 8691-8695 (1991)
2034	Kita, Y., <i>et al.</i> , "ErbB Receptor Activation, Cell Morphology Changes, and Apoptosis Induced by Anti-Her2 Monoclonal Antibodies," <i>Biochemical and Biophysical Research Communications</i> 226: 59-69 (1996)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.